PetVivo

PetVivo is a biomedical device company that specializes in innovative medical devices and therapeutics for companion animals.

Offering Type:
Dual Listing

Asset Type:
Common Stock (Equity)

Upstream Ticker Symbol:
PETV

Purchase Shares

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center

Visit the Support Center for help on Upstream.

PetVivo Holdings Inc. is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

  • SpryngTM, with our OsteoCushionTM Technology, is a veterinary device that is indicated to aid in the management of noninfectious sources of joint pain including joint instability, abnormal joint biomechanics, degenerative joint disease and osteoarthritis.
  • Distribution Agreements with MWI and Covetrus with shipments to multiple distribution centers throughout the U.S.
  • Strong IP portfolio with twelve U.S. and nine foreign-issued patents
  • Focus on an estimated $11B companion animal veterinary care and product sales market.
  • The National Institutes of Health awarded the Company a series of grants totaling approximately $7.0M for the development of vascular grafts and other devices. The work derived from the vascular graft grant produced the completion of pre-clinical testing required for an FDA small-diameter vascular graft clinical trial.
  • PetVivo merged with Gel-Del Technologies, Inc., which is now a wholly-owned subsidiary of the Company, PetVivo Holdings, Inc.
  • PetVivo’s new facility, positioned to scale; existing facility can produce up to 500K units annually, equaling up to $100M in revenue.
  • With a robust pipeline of products at different stages of development and commercialization, PetVivo’s strategy focuses on veterinary medical devices which do not require FDA premarket approval, creating a faster path to market.

Company Particulars:

Regulatory Filings

Listing Particulars

Corporate Presentation


Website

News

Regulatory Filings

Stay Connected

FAQ

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center.

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center.

U.S. PERSONS MAY NOT DEPOSIT, BUY, OR SELL SECURITIES ON UPSTREAM. THE OFFER SHARES ARE ONLY SUITABLE FOR INVESTORS: (I) WHO UNDERSTAND THE POTENTIAL RISK OF CAPITAL LOSS AND THAT THERE MAY BE LIMITED LIQUIDITY IN THE UNDERLYING INVESTMENTS OF THE COMPANY; (II) FOR WHOM AN INVESTMENT IN THE OFFER SHARES IS PART OF A DIVERSIFIED INVESTMENT PROGRAM; AND (III) WHO FULLY UNDERSTAND AND ARE WILLING TO ASSUME THE RISKS INVOLVED IN SUCH AN INVESTMENT PROGRAM. IT SHOULD BE REMEMBERED THAT THE PRICE OF THE SHARES AND THE INCOME FROM THEM CAN GO DOWN AS WELL AS UP. THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION A CROWD FINANCED INITIAL PUBLIC OFFERING INVESTMENT INVOLVES RISK. YOU SHOULD NOT INVEST ANY FUNDS IN THIS OFFERING UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED OR APPROVED BY UPSTREAM, MERJ, HORIZON FINTEX ADVISORS, THE REPUBLIC OF SEYCHELLES OR ANY FEDERAL SECURITIES COMMISSION OR REGULATORY AUTHORITY OF ANY OTHER JURISDICTION. THE COMPANY URGES YOU TO CAREFULLY REVIEW THE PROSPECTUS, PARTICULARLY THE SECTION TITLED "RISK FACTORS" IN THE PROSPECTUS FOR A MORE COMPLETE DISCUSSION OF THE RISK OF AN INVESTMENT IN THE COMPANY. FURTHERMORE, THESE AUTHORITIES HAVE NOT PASSED UPON THE ACCURACY OR ADEQUACY OF THE PROSPECTUS OR COMPLETENESS OF ANY OFFERING DOCUMENT OR LITERATURE. THE WEBSITE AND PROSPECTUS CONTAINS FORWARD LOOKING STATEMENTS BASED ON ASSUMPTIONS AND REFLECTS THE DIRECTORS EXPECTATIONS, ESTIMATES AND PROJECTIONS OF FUTURE EVENTS. FORWARD LOOKING STATEMENTS INCLUDE WITHOUT LIMITATION, STATEMENTS REGARDING THE PERFORMANCE, PROSPECTS, OPPORTUNITIES, PRIORITIES, TARGETS, GOALS, OBJECTIVES, STRATEGIES, GROWTH AND OUTLOOK OF THE COMPANY. OFTEN, BUT NOT ALWAYS, FORWARD LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF WORDS SUCH AS "EXPECTS", "ANTICIPATES", "PLANS", "BELIEVES", "ESTIMATES", "SEEKS", "INTENDS", "TARGETS", "PROJECTS", "FORECASTS", OR VARIATIONS (INCLUDING NEGATIVE VARIATIONS) OF SUCH WORDS AND PHRASES, OR STATE THAT CERTAIN ACTIONS, EVENTS OR RESULTS "MAY", "COULD", "WOULD", "MIGHT" OR "WILL" BE TAKEN, OCCUR OR BE ACHIEVED. FORWARD LOOKING STATEMENTS ARE BASED UPON CERTAIN MATERIAL FACTORS AND ASSUMPTIONS THAT WERE APPLIED IN DRAWING A CONCLUSION OR MAKING A FORECAST OR PROJECTION, INCLUDING ASSUMPTIONS AND ANALYSES MADE BY THE DIRECTORS IN THE LIGHT OF THEIR EXPERIENCE AND PERCEPTION OF HISTORICAL TRENDS, CURRENT CONDITIONS AND EXPECTED FUTURE DEVELOPMENTS, AS WELL AS OTHER FACTORS THAT ARE BELIEVED TO BE APPROPRIATE IN THE CIRCUMSTANCES. ALSO, FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT ARE BEYOND THE DIRECTORS CONTROL AND WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENT TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. SUCH MATERIAL FACTORS AND ASSUMPTIONS AND RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHERS, THOSE WHICH ARE INCORPORATED INTO THE PROSPECTUS AND QUALIFY ANY AND ALL FORWARD-LOOKING STATEMENTS MADE IN THE PROSPECTUS.